Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Exenatide

What is Exenatide?

CAS No: 141758-74-9

Exenatide is a biopharmaceutical product produced by living cell expression systems, whose pharmacological activity arises from specific binding interactions with biological targets including cell-surface receptors, soluble cytokines, or enzyme active sites. The manufacturing process—encompassing upstream cell culture, downstream purification, and formulation—is intrinsically linked to product quality and must be validated to ensure consistent structure and potency. PDE assessment for biological compounds focuses on on-target pharmacological hazard, with occupational inhalation exposure to protein aerosols during fill-finish operations representing the primary manufacturing exposure concern.

The OEB assigned to Exenatide in pharmaceutical manufacturing is determined by structured potency banding based on its pharmacological target, NOAEL from repeat-dose studies, genotoxic classification under ICH M7, and reproductive toxicant status.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Exenatide is a synthetic peptide of 39 amino acids that acts as a GLP-1 receptor agonist and is given by injection in the treatment of type 2 diabetes. As a peptide drug, it benefits from an assessment that considers its potency and handling risks in manufacturing, filling and cleaning.

A PDE or ADE sets a health-based limit on daily exposure to Exenatide from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Each operation is reviewed for how exposure could occur, such as dust, aerosols, or surface residues. The exposure limit is then linked to the task, the containment in place, and the cleaning procedures used. This supports proportionate controls and helps show that carryover into other products is managed in a documented, scientifically justified way.

An assessment should be reviewed when new toxicological data become available, when the intended use or handling conditions change, or when relevant guidance is updated. Periodic review keeps the health-based limit aligned with current scientific knowledge and regulatory expectations. Any change to the conclusion should be documented with a clear rationale for the revision.

Carryover is evaluated by comparing possible residue levels in the next product with the health-based limit. The assessment considers shared equipment, cleaning effectiveness, batch sizes, and the maximum daily dose of the following product. When the residue is kept below the limit, the risk of cross-contamination can be shown to be controlled and documented.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Exenatide in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Evidence may include non-clinical studies, clinical data, post-marketing safety information where available, and the mechanism of action. The quality and relevance of each source are weighed when selecting the critical effect. Where gaps remain, a documented, risk-based approach is used and each assumption is recorded in the report so that reviewers can follow the reasoning.

Yes, where the substance may be handled in manufacturing, formulation, or cleaning. Peptide-based active substances can be biologically potent, so exposure limits help protect workers and prevent cross-contamination. The assessment should explain which route and exposure scenario the limit applies to, and how the available evidence was interpreted for this type of substance.

Potent pharmacological activity may lead to effects at very low exposure, so the mechanism of action and potency are central to selecting the critical effect. The assessment considers whether effects relate to the intended pharmacology and how sensitive they may be in exposed people. These considerations can lead to a lower, more conservative health-based limit.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Exenatide to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo